OpenLB
Open Library of Bioscience
Advanced Search
Heliyon
Feb 29, 2024;10 (4): e26193.

Tuberculosis vaccine developments and efficient delivery systems: A comprehensive appraisal.

Rasoul Hoseinpour, Alka Hasani, Behzad Baradaran, Jalal Abdolalizadeh, Roya Salehi, Akbar Hasani, Edris Nabizadeh, Mina Yekani, Roqaiyeh Hasani, Hossein Samadi Kafil, Khalil Azizian, Mohammad Yousef Memar
Author Information
  1. Rasoul Hoseinpour: Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  2. Alka Hasani: Immunology Research Center (IRC), Tabriz University of Medical Sciences, Tabriz, Iran.
  3. Behzad Baradaran: Immunology Research Center (IRC), Tabriz University of Medical Sciences, Tabriz, Iran.
  4. Jalal Abdolalizadeh: Drug Applied Research Center and Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
  5. Roya Salehi: Drug Applied Research Center and Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
  6. Akbar Hasani: Department of Clinical Biochemistry and Applied Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
  7. Edris Nabizadeh: Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  8. Mina Yekani: Department of Microbiology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
  9. Roqaiyeh Hasani: Istanbul Okan University, 34959 Tuzla/İstanbul, Turkey.
  10. Hossein Samadi Kafil: Department of Medical Microbiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  11. Khalil Azizian: Department of Microbiology, Faculty of Medicine, Kurdistan University of Medical Science, Sanandaj, Iran.
  12. Mohammad Yousef Memar: Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
PMID: 38404880 DOI: 10.1016/j.heliyon.2024.e26193

Abstract

Despite the widespread use of the Bacillus Calmette-Guérin (BCG) vaccine, (MTB) continues to be a global burden. Vaccination has been proposed to prevent and treat tuberculosis (TB) infection, and several of them are in different phases of clinical trials. Though vaccine production is in progress but requires more attention. There are several TB vaccines in the trial phase, most of which are based on a combination of proteins/adjuvants or recombinant viral vectors used for selected MTB antigens. In this review, we attempted to discuss different types of TB vaccines based on the vaccine composition, the immune responses generated, and their clinical trial phases. Furthermore, we have briefly overviewed the effective delivery systems used for the TB vaccine and their effectiveness in different vaccines.

Keywords

Bacillus Calmette–Guérin Delivery systems Tuberculosis Vaccine

References

  1. Pharmaceutics. 2020 Dec 16;12(12): [PMID: 33339306]
  2. Hum Vaccin Immunother. 2017 Sep 2;13(9):1960-1971 [PMID: 28604170]
  3. Lancet. 2013 Mar 23;381(9871):1021-8 [PMID: 23391465]
  4. Infect Immun. 2007 Jan;75(1):408-16 [PMID: 17074845]
  5. Int J Tuberc Lung Dis. 2008 Dec;12(12):1376-9 [PMID: 19017445]
  6. Lancet Respir Med. 2015 Mar;3(3):190-200 [PMID: 25726088]
  7. Expert Rev Mol Diagn. 2009 May;9(4):325-41 [PMID: 19435455]
  8. Acta Pharm. 2015 Jun;65(2):105-16 [PMID: 26011928]
  9. Adv Drug Deliv Rev. 2003 Feb 24;55(3):329-47 [PMID: 12628320]
  10. Infect Immun. 2014 Sep;82(9):3979-85 [PMID: 25024362]
  11. Viruses. 2023 Oct 19;15(10): [PMID: 37896900]
  12. J Cell Physiol. 2019 Aug;234(8):12530-12536 [PMID: 30633361]
  13. Nanotechnology. 2017 Apr 21;28(16):165101 [PMID: 28206982]
  14. Vaccine. 2017 Mar 14;35(12):1652-1661 [PMID: 28216183]
  15. Sci Rep. 2016 Nov 02;6:36355 [PMID: 27805026]
  16. Int J Tuberc Lung Dis. 2009 Nov;13(11):1331-44 [PMID: 19861003]
  17. Medicine (Baltimore). 2018 Nov;97(45):e13120 [PMID: 30407329]
  18. Immunity. 2010 Oct 29;33(4):567-77 [PMID: 21029966]
  19. N Engl J Med. 2020 Apr 16;382(16):1576-1577 [PMID: 32294368]
  20. Scand J Immunol. 2016 Oct;84(4):204-10 [PMID: 27454335]
  21. J Immunol. 2008 Oct 1;181(7):4955-64 [PMID: 18802099]
  22. J Immunol. 2013 Jun 15;190(12):6311-9 [PMID: 23677471]
  23. Wellcome Open Res. 2018 Sep 19;3:121 [PMID: 30687792]
  24. BMC Infect Dis. 2019 Jul 1;19(1):568 [PMID: 31262260]
  25. PLoS One. 2008 Sep 08;3(9):e3116 [PMID: 18776936]
  26. Microb Pathog. 2021 May;154:104842 [PMID: 33762199]
  27. Lancet Infect Dis. 2014 Oct;14(10):939-46 [PMID: 25151225]
  28. Hum Vaccin Immunother. 2016 Apr 2;12(4):960-70 [PMID: 27002369]
  29. PLoS Pathog. 2020 Apr 2;16(4):e1008404 [PMID: 32240273]
  30. Sci Rep. 2019 Oct 29;9(1):15560 [PMID: 31664157]
  31. PLoS One. 2012;7(3):e32959 [PMID: 22442674]
  32. Vaccine. 2018 May 11;36(20):2850-2854 [PMID: 29655632]
  33. Vaccine. 2020 Jan 22;38(4):779-789 [PMID: 31735500]
  34. Eur J Immunol. 2015 Mar;45(3):780-93 [PMID: 25430701]
  35. Artif Cells Nanomed Biotechnol. 2017 Mar;45(2):291-296 [PMID: 26924121]
  36. Clin Exp Immunol. 2006 Dec;146(3):390-9 [PMID: 17100757]
  37. Front Immunol. 2019 Apr 30;10:894 [PMID: 31114572]
  38. Front Immunol. 2017 Sep 19;8:1147 [PMID: 28974949]
  39. Vaccine. 2015 Aug 7;33(33):4130-40 [PMID: 26095509]
  40. N Engl J Med. 2020 Apr 16;382(16):1577 [PMID: 32294369]
  41. NPJ Vaccines. 2018 Sep 4;3:34 [PMID: 30210819]
  42. Vaccine. 2010 Apr 30;28(20):3571-81 [PMID: 20226890]
  43. Front Immunol. 2018 Feb 27;9:310 [PMID: 29535714]
  44. Vaccine. 2000 Aug 15;19(1):122-31 [PMID: 10924794]
  45. J Clin Tuberc Other Mycobact Dis. 2019 Dec 12;18:100141 [PMID: 31890902]
  46. Vaccine. 2013 Feb 18;31(9):1340-8 [PMID: 23290835]
  47. Immune Netw. 2018 Apr 03;18(2):e17 [PMID: 29732235]
  48. Adv Biosyst. 2019 Mar;3(3):e1800287 [PMID: 32627400]
  49. Tuberculosis (Edinb). 2014 Dec;94(6):564-78 [PMID: 25305000]
  50. Drug Res (Stuttg). 2022 Jun;72(5):255-258 [PMID: 35318622]
  51. Lancet. 2010 Jun 12;375(9731):2110-9 [PMID: 20488515]
  52. Vaccine. 2011 Aug 5;29(34):5645-51 [PMID: 21689705]
  53. PLoS Med. 2019 Apr 30;16(4):e1002790 [PMID: 31039172]
  54. Vaccine. 2013 Apr 19;31(17):2196-206 [PMID: 22643213]
  55. Biomed Rep. 2016 May;4(5):595-600 [PMID: 27123253]
  56. Methods Mol Biol. 2016;1404:377-392 [PMID: 27076312]
  57. PLoS One. 2016 Dec 20;11(12):e0168521 [PMID: 27997597]
  58. Int J Nanomedicine. 2013;8:835-43 [PMID: 23486691]
  59. BMC Infect Dis. 2014;14 Suppl 1:S2 [PMID: 24564340]
  60. PLoS One. 2012;7(6):e39909 [PMID: 22768165]
  61. Lancet Microbe. 2023 Jan;4(1):e20 [PMID: 36521512]
  62. Indian J Tuberc. 2018 Oct;65(4):335-344 [PMID: 30522622]
  63. Microb Pathog. 2018 Dec;125:507-513 [PMID: 30352265]
  64. Microorganisms. 2019 Aug 12;7(8): [PMID: 31409028]
  65. Clin Infect Dis. 2018 Feb 1;66(4):554-563 [PMID: 29028973]
  66. Vaccine. 2009 Jun 19;27(30):4010-7 [PMID: 19389445]
  67. Curr Opin Pulm Med. 2014 May;20(3):294-300 [PMID: 24626237]
  68. Vaccine. 2015 Dec 16;33(51):7217-7224 [PMID: 26552000]
  69. Lancet Respir Med. 2021 Apr;9(4):373-386 [PMID: 33306991]
  70. Vaccine. 2016 Apr 27;34(19):2179-87 [PMID: 27005808]
  71. Expert Rev Vaccines. 2014 May;13(5):619-30 [PMID: 24702486]
  72. Tuberculosis (Edinb). 2016 Dec;101:201-209 [PMID: 27865392]
  73. PLoS One. 2014 Dec 09;9(12):e114602 [PMID: 25490675]
  74. Front Immunol. 2019 Jun 12;10:1349 [PMID: 31293568]
  75. J Biotechnol. 2002 May;90(3-4):195-229 [PMID: 12071226]
  76. Expert Rev Vaccines. 2013 Aug;12(8):829-31 [PMID: 23944644]
  77. Vaccines (Basel). 2023 May 04;11(5): [PMID: 37243045]
  78. Vaccine. 2009 Jul 16;27(33):4388-401 [PMID: 19450632]
  79. N Engl J Med. 2019 Dec 19;381(25):2429-2439 [PMID: 31661198]
  80. PLoS One. 2019 May 23;14(5):e0217091 [PMID: 31120957]
  81. Tuberculosis (Edinb). 2006 May-Jul;86(3-4):273-89 [PMID: 16545981]
  82. Ther Adv Vaccines. 2015 May;3(3):66-75 [PMID: 26288734]
  83. Nanoscale Res Lett. 2014 May 21;9(1):247 [PMID: 24994950]
  84. Clin Infect Dis. 2015 Oct 15;61Suppl 3:S102-18 [PMID: 26409271]
  85. Vaccine. 2011 Mar 3;29(11):2100-9 [PMID: 21256189]
  86. Am J Respir Crit Care Med. 2019 Jan 15;199(2):220-231 [PMID: 30092143]
  87. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):370-377 [PMID: 30691310]
  88. Vaccine. 2010 Jan 22;28(4):1084-93 [PMID: 19896449]
  89. Vaccine. 2015 Jul 9;33(30):3592-9 [PMID: 26048780]
  90. Vaccine. 2014 Jul 23;32(34):4324-32 [PMID: 24951861]
  91. Vaccine. 2011 Sep 16;29(40):6959-66 [PMID: 21787826]
  92. EClinicalMedicine. 2020 Mar 18;21:100313 [PMID: 32382714]
  93. Vaccines (Basel). 2021 Nov 03;9(11): [PMID: 34835204]
  94. PLoS One. 2009 Jun 03;4(6):e5771 [PMID: 19492047]
  95. J Virol Methods. 2010 Jul;167(1):17-22 [PMID: 20304011]
  96. PLoS Negl Trop Dis. 2017 May 4;11(5):e0005440 [PMID: 28472067]
  97. Cent Eur J Immunol. 2017;42(2):196-204 [PMID: 28867962]
  98. Scand J Immunol. 2008 Jun;67(6):610-7 [PMID: 18397200]
  99. Mol Biotechnol. 2013 Jan;53(1):92-107 [PMID: 23001867]
  100. PLoS One. 2017 May 12;12(5):e0175215 [PMID: 28498853]
  101. Expert Opin Drug Deliv. 2012 Apr;9(4):443-55 [PMID: 22413847]
  102. Nanomedicine. 2012 Nov;8(8):1337-44 [PMID: 22406425]
  103. Clin Vaccine Immunol. 2008 Aug;15(8):1229-37 [PMID: 18524883]
  104. Clin Vaccine Immunol. 2017 Feb 6;24(2): [PMID: 27974398]
  105. Sci Transl Med. 2010 Oct 13;2(53):53ra74 [PMID: 20944089]
  106. Rep Biochem Mol Biol. 2019 Jan;7(2):156-166 [PMID: 30805395]
  107. Clin Vaccine Immunol. 2008 May;15(5):893-6 [PMID: 18337379]
  108. Clin Vaccine Immunol. 2015 Dec 09;23(2):137-47 [PMID: 26656121]
  109. Drug Deliv. 2015 May;22(3):328-34 [PMID: 24611942]
  110. Sci Rep. 2016 Jan 21;6:19570 [PMID: 26791076]
  111. Vaccine. 2017 Jan 3;35(1):132-141 [PMID: 27866772]
  112. Hum Vaccin. 2009 Jul;5(7):475-82 [PMID: 19587528]
  113. PLoS One. 2011;6(9):e23826 [PMID: 21909406]
  114. Vaccine. 2015 Jul 31;33(32):4025-34 [PMID: 26072017]
  115. Vaccine. 2014 Dec 12;32(52):7098-107 [PMID: 25454872]
  116. Trials. 2018 Jan 10;19(1):24 [PMID: 29321075]
  117. Sci Transl Med. 2013 Oct 2;5(205):205ra134 [PMID: 24089406]
  118. Vaccine. 2016 May 11;34(22):2477-82 [PMID: 27060379]
  119. Cell Rep Med. 2021 Jan 19;2(1):100185 [PMID: 33521699]
  120. Expert Rev Vaccines. 2012 Oct;11(10):1221-33 [PMID: 23176655]
  121. J Immunol. 2004 Nov 15;173(10):6357-65 [PMID: 15528375]
  122. Vaccine. 2019 May 16;37(22):2960-2966 [PMID: 31010716]
  123. Vaccine. 2015 Apr 8;33(15):1890-6 [PMID: 25698492]
  124. Mol Ther. 2009 Jun;17(6):1093-100 [PMID: 19319120]
  125. Pharmaceuticals (Basel). 2023 Oct 09;16(10): [PMID: 37895899]
  126. N Engl J Med. 2018 Oct 25;379(17):1621-1634 [PMID: 30280651]
  127. Int J Infect Dis. 2015 Mar;32:5-12 [PMID: 25809749]
  128. Med J Armed Forces India. 2019 Jan;75(1):18-24 [PMID: 30705473]
  129. Lepr Rev. 2005 Jun;76(2):127-43 [PMID: 16038246]
  130. Vaccine. 2012 Sep 28;30(44):6294-300 [PMID: 22885013]
  131. Vaccine. 2004 Apr 16;22(13-14):1609-15 [PMID: 15068842]
  132. NPJ Vaccines. 2021 Jan 4;6(1):4 [PMID: 33397991]
  133. PLoS Pathog. 2012;8(5):e1002607 [PMID: 22589713]
  134. Tuberculosis (Edinb). 2016 Dec;101:164-173 [PMID: 27865389]
  135. Expert Rev Vaccines. 2017 Jun;16(6):565-576 [PMID: 28447476]
  136. Artif Cells Nanomed Biotechnol. 2016;44(2):532-9 [PMID: 25307269]
  137. Am J Respir Crit Care Med. 2017 May 1;195(9):1171-1180 [PMID: 28060545]
  138. Nat Med. 2011 Sep 04;17(10):1261-8 [PMID: 21892180]
  139. Vaccine. 2016 May 5;34(21):2430-2436 [PMID: 27026148]
  140. Biomacromolecules. 2003 May-Jun;4(3):828-34 [PMID: 12741805]
  141. Vaccine. 2014 Oct 14;32(45):5998-6004 [PMID: 25211768]
  142. Int J Biol Macromol. 2018 Dec;120(Pt A):180-188 [PMID: 30098365]
  143. Vaccine. 2013 Oct 1;31(42):4867-73 [PMID: 23965219]
  144. PLoS One. 2010 Nov 29;5(11):e15043 [PMID: 21124731]
  145. Curr Drug Deliv. 2019;16(5):430-443 [PMID: 30760185]
  146. Pharmaceutics. 2011 Aug 05;3(3):458-73 [PMID: 24310590]
Journal Article Review
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0vaccineTBdifferentvaccinesBacillusMTBseveralphasesclinicaltrialbaseduseddeliverysystemsTuberculosisDespitewidespreaduseCalmette-GuérinBCGcontinuesglobalburdenVaccinationproposedpreventtreattuberculosisinfectiontrialsThoughproductionprogressrequiresattentionphasecombinationproteins/adjuvantsrecombinantviralvectorsselectedantigensreviewattempteddiscusstypescompositionimmuneresponsesgeneratedFurthermorebrieflyoverviewedeffectiveeffectivenessdevelopmentsefficientsystems:comprehensiveappraisalCalmette–GuérinDeliveryVaccine

Similar Articles

Cited By